1239016-39-7

Basic information

• Product Name: (R)-2-(2,3-dichlorophenyl)propanoic acid
• Synonyms: (R)-2-(2,3-dichlorophenyl)propanoic acid
• CAS NO: 1239016-39-7
• Molecular Weight: 219.067
• Mol File: 1239016-39-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (R)-2-(2,3-dichlorophenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(2,3-dichlorophenyl)propanoic acid(1239016-39-7)
• EPA Substance Registry System: (R)-2-(2,3-dichlorophenyl)propanoic acid(1239016-39-7)

Safety Data

• Hazardous Substances Data: 1239016-39-7(Hazardous Substances Data)

Upstream product

• 10236-60-9 (2,3-dichlorophenyl)acetic acid 
• 1434517-97-1 (4R)-4-benzyl-3-(2-(2,3-dichlorophenyl)propanoyl)oxazolidin-2-one 
• 1434517-96-0 (R)-4-benzyl-3-(2-(2,3-dichlorophenyl)acetyl)oxazolidin-2-one 
• 82302-32-7 2-(2,3-dichlorophenyl)acetyl chloride 
• 2012-77-3 2-(2,3-dichlorophenyl)propanoic acid 
• 62784-66-1 bis(1-naphthyl)methanol 

Downstream Products

• 1434517-76-6 (R)-2-(2,3-dichlorophenyl)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS

Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.

Kinetic resolution of racemic α-arylalkanoic acids with achiral alcohols via the asymmetric esterification using carboxylic anhydrides and acyl-transfer catalysts

A variety of optically active carboxylic esters are produced by the kinetic resolution of racemic α-substituted carboxylic acids using achiral alcohols, aromatic or aliphatic carboxylic anhydrides, and chiral acyl-transfer catalysts. The combination of 4-methoxybenzoic anhydride (PMBA) or pivalic anhydride with the modified benzotetramisole-type catalyst ((S)-β-Np-BTM) is the most effective for promotion of the enantioselective coupling reaction between racemic carboxylic acids and a novel nucleophile, bis(α-naphthyl) methanol, to give the corresponding esters with high ees. This protocol was successfully applied to the production of nonracemic nonsteroidal anti-inflammatory drugs from racemic compounds utilizing the transacylation process to generate the mixed anhydrides from the acid components with the suitable carboxylic anhydrides.